AgomAb shares surge 93.47% after hours following $200M IPO closure led by J.P. Morgan and Morgan Stanley.

AgomAb Therapeutics (AGMB) surged 93.47% in after-hours trading following the announcement of its successful $200 million initial public offering (IPO). The clinical-stage biopharma company closed the offering of 12.5 million American Depositary Shares at $16.00 per ADS, with shares commencing trading on the Nasdaq Global Select Market on February 6, 2026. The IPO, managed by J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen, generated gross proceeds before underwriting costs, signaling strong investor confidence in AgomAb’s focus on disease-modifying therapies for chronic fibrotic diseases. The after-hours price jump reflects market optimism over the capital raise, which will support the company’s development pipeline targeting immunology and inflammatory conditions.